Salicylic acid

Description

No relevant information is available for SPL code 34089-3.

Uses and Indications

This drug is indicated for the removal of common and plantar warts. Common warts are characterized by their rough, "cauliflower-like" surface appearance, while plantar warts are specifically located on the bottom of the foot, presenting tenderness and disrupting the normal footprint pattern.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The recommended dosage and administration details for this medication are not specified in the provided information. Healthcare professionals are advised to consult the complete drug insert for specific dosage instructions.

Additionally, the route, method, and frequency of administration are not detailed in the text. It is essential to refer to the complete drug insert for comprehensive administration instructions.

Contraindications

Use is contraindicated in the following situations:

Application is not recommended on irritated skin or any area that is infected or reddened, as this may exacerbate the condition. Additionally, the product should not be applied to moles, birthmarks, warts with hair growing from them, or warts located on the face or mucous membranes due to the potential for adverse reactions.

Warnings and Precautions

To avoid the risk of suffocation, it is imperative to keep this plastic bag away from infants and children. This bag should not be used in cribs, beds, carriages, or playpens, as it poses a significant hazard. It is essential to recognize that this bag is not a toy.

General precautions must be observed, particularly the necessity to keep the product out of reach of children to prevent accidental exposure or misuse.

Healthcare professionals should advise patients to discontinue use and consult a physician if the product is applied to irritated skin or any area that is infected or reddened. This includes moles, birthmarks, warts with hair growing from them, and warts located on the face or mucous membranes. Such precautions are critical to ensure patient safety and to avoid exacerbating existing skin conditions.

Side Effects

Patients should be aware of the potential risks associated with the use of this product. There are specific warnings regarding the danger of suffocation; therefore, it is crucial to keep the plastic bag away from babies and children. The bag should not be used in cribs, beds, carriages, or playpens, as it is not a toy.

Additionally, patients are advised to discontinue use if the product is applied to irritated skin or any area that is infected or reddened. This includes moles, birthmarks, warts with hair growing from them, and warts located on the face or mucous membranes. Adhering to these guidelines is essential to minimize the risk of adverse reactions.

Drug Interactions

There are no specific drug interactions identified for this medication. Additionally, no laboratory test interactions have been reported. Therefore, no dosage adjustments or monitoring recommendations are necessary based on drug or laboratory test interactions.

Packaging & NDC

Below are the non-prescription pack sizes of Skin Tag One Step Patches. Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be closely monitored when using this product due to safety concerns. To avoid the risk of suffocation, it is imperative to keep the plastic bag away from infants and children. The bag should not be used in cribs, beds, carriages, or playpens, as it poses a potential hazard. Additionally, it is essential to keep this product out of reach of children to prevent any accidental exposure or misuse.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

There is currently no information available regarding the use of Skin Tag One Step Patches during pregnancy. This includes any safety concerns, dosage modifications, or special precautions that may be necessary for pregnant patients. Healthcare professionals should exercise caution and consider the lack of data when prescribing this product to women who are pregnant or may become pregnant. It is advisable to weigh the potential benefits against any unknown risks to fetal outcomes.

Lactation

There is no specific information available regarding the use of this drug in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider the absence of data when advising lactating mothers about the use of this medication.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data regarding its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and consider general principles of management for suspected cases of drug overdosage.

It is essential to monitor patients closely for any signs or symptoms that may arise following an overdose. Common symptoms may include, but are not limited to, altered mental status, cardiovascular instability, and gastrointestinal disturbances.

In the event of suspected overdosage, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and ensuring adequate circulation.

Activated charcoal may be considered if the patient presents within a suitable timeframe and is alert enough to protect their airway. Additionally, specific antidotes or treatments should be administered as indicated based on the clinical scenario and the substances involved.

Continuous monitoring of vital signs and laboratory parameters is recommended to assess the patient's condition and guide further management. Consultation with a poison control center or a medical toxicologist may also be beneficial in complex cases.

Overall, the management of overdosage should be tailored to the individual patient, taking into account their clinical presentation and the specific circumstances surrounding the overdose.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the compound in these areas.

Postmarketing Experience

No postmarketing experience details are available in the insert text.

Patient Counseling

Healthcare providers should advise patients to keep the medication out of reach of children to prevent accidental ingestion or misuse.

Patients should be instructed not to use the medication on irritated skin or on any area that is infected or reddened. Additionally, it is important to inform patients that the medication should not be applied to moles, birthmarks, or warts with hair growing from them, nor should it be used on warts located on the face or mucous membranes. This guidance is essential to ensure safe and effective use of the medication.

Storage and Handling

The product is supplied in a configuration that ensures optimal handling and storage. It should be stored at room temperature, specifically in a cool, dry place to maintain its integrity. It is essential to protect the product from light exposure to prevent degradation. Additionally, to ensure safety, the product must be kept out of reach of children.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Skin Tag One Step Patches, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)